NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million

Reuters03-24

NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million

NRx Pharma published its annual report on Form 10-K for the year ended Dec. 31, 2025, reporting a net loss of USD 28.6 million.
Net patient service revenue was USD 1.2 million, reflecting patient services provided by Dura following its acquisition on Sept. 8, 2025.
Research and development expense fell 39.07% to USD 3.8 million, driven mainly by lower clinical trials and development spending and reduced regulatory and process development consulting costs.
Cash was USD 7.8 million at Dec. 31, 2025, while net cash used in operating activities rose 32.66% to USD 14.1 million.
Management said it plans to pursue additional equity or debt financing and concluded substantial doubt exists about its ability to continue as a going concern for at least 12 months from issuance of the financial statements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009418), on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621844320?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621844320","market":"us","top_or_hot":-1,"title":"NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          NRx Pharma published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, reporting a net loss of USD 28.6 million.\n        </li>\n<li>\n          Net patient service revenue was USD 1.2 million, reflecting patient services provided by Dura following its acquisition on Sept. 8, 2025.\n        </li>\n<li>\n          Research and development expense fell 39.07% to USD 3.8 million, driven mainly by lower clinical trials and development spending and reduced regulatory and process development consulting costs.\n        </li>\n<li>\n          Cash was USD 7.8 million at Dec. 31, 2025, while net cash used in operating activities rose 32.66% to USD 14.1 million.\n        </li>\n<li>\n          Management said it plans to pursue additional equity or debt financing and concluded substantial doubt exists about its ability to continue as a going concern for at least 12 months from issuance of the financial statements.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRXP\">NRX Pharmaceuticals Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009418), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          NRx Pharma published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, reporting a net loss of USD 28.6 million.\n        </li>\n<li>\n          Net patient service revenue was USD 1.2 million, reflecting patient services provided by Dura following its acquisition on Sept. 8, 2025.\n        </li>\n<li>\n          Research and development expense fell 39.07% to USD 3.8 million, driven mainly by lower clinical trials and development spending and reduced regulatory and process development consulting costs.\n        </li>\n<li>\n          Cash was USD 7.8 million at Dec. 31, 2025, while net cash used in operating activities rose 32.66% to USD 14.1 million.\n        </li>\n<li>\n          Management said it plans to pursue additional equity or debt financing and concluded substantial doubt exists about its ability to continue as a going concern for at least 12 months from issuance of the financial statements.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRXP\">NRX Pharmaceuticals Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009418), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL6r5ppt:1","article_id":"2621844320","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621844320","pubTimestamp":1774297934,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NRx Pharma published its annual report on Form 10-K for the year ended Dec. 31, 2025, reporting a net loss of USD 28.6 million.Net patient service revenue was USD 1.2 million, reflecting patient services provided by Dura following its acquisition on Sept. 8, 2025.Research and development expense fell 39.07% to USD 3.8 million, driven mainly by lower clinical trials and development spending and reduced regulatory and process development consulting costs.Cash was USD 7.8 million at Dec. 31, 2025, while net cash used in operating activities rose 32.66% to USD 14.1 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data G","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NRXP":"NRX Pharmaceuticals Inc."},"translate_title":"NRX Pharmaceuticals 2025财年净亏损为2900万美元，利息支出增长192%至100万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9},"content_text":"NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million\n    \n\n\n          NRx Pharma published its annual report on Form 10-K for the year ended Dec. 31, 2025, reporting a net loss of USD 28.6 million.\n        \n\n          Net patient service revenue was USD 1.2 million, reflecting patient services provided by Dura following its acquisition on Sept. 8, 2025.\n        \n\n          Research and development expense fell 39.07% to USD 3.8 million, driven mainly by lower clinical trials and development spending and reduced regulatory and process development consulting costs.\n        \n\n          Cash was USD 7.8 million at Dec. 31, 2025, while net cash used in operating activities rose 32.66% to USD 14.1 million.\n        \n\n          Management said it plans to pursue additional equity or debt financing and concluded substantial doubt exists about its ability to continue as a going concern for at least 12 months from issuance of the financial statements.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009418), on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621844320","isCrawlerRequest":true}